Neuro-Oncology Reviews
Volume
28 Number 13
10 May 2026
Home > Publications > Neuro-Oncology Reviews > Volume 28, Year 2026 > Number 13, 10 May
Khaliq HMH.
Tumour Microenvironment in
Brain Cancer: A Neural Niche or a Hijacked Memory System?
J
Coll Physicians Surg Pak. 2026 May;36(5):569-570. doi:
10.29271/jcpsp.2026.05.569. PMID:
42152192. ˍ
Arjeini Y, Khalili Dermani S, Sadeh S, Abdolalipour E, Saberpour
M, Zargaran H, Mohebbi SR, Ghaemi A.
Oncolytic
viruses in brain cancer therapy: advances, challenges, and
clinical trial outcomes.
Immunotherapy.
2026 May 4;18(3):249-270. doi:
10.1080/1750743X.2026.2640755. PMID:
42077101˰ ˍ
Leeper HE, Oliver K, Bulbeck H, Johnson MO.
Translating
Cancer Science Into Cancer Care: Using Serious Illness
Communication Frameworks to Deliver High-Quality Person-Centered
Care in Neuro-Oncology.
Am
Soc Clin Oncol Educ Book. 2026 May 8;46(3):e525426.
doi:
10.1200/EDBK-26-525426. PMID:
42102343. ˍ
Manoharan N, Armitage N, Virdun C.
Corticosteroid
use in pediatric neuro-oncology symptom management: A rapid
review.
Neurooncol
Pract. 2025 Sep 17;13(2):227-237. doi:
10.1093/nop/npaf097. PMID:
42111026. ˍ
Lindsay H, Bouffet E.
The future of
targeted therapies for pediatric central nervous system tumors.
Neurooncol
Adv. 2025 Dec 2;8(Suppl 2):ii78-ii91. doi:
10.1093/noajnl/vdaf188. PMID:
42137218. ˍ
Ghoche MT, Miki K, Yuan F, Gecici NN, Mantica M, Marker DF, Pearce
TM, Zinn PO, Ziv MN, Drappatz J, Abdullah KG.
Clinical
characteristics and outcomes of adult IDH-mutant brainstem
gliomas: Institutional case series and systematic
review.
Neurooncol
Adv. 2026 Apr 7;8(1):vdag091. doi:
10.1093/noajnl/vdag091. PMID:
42079759. ˍ
Filardo A, Coscarella I, Bria J, Di Vito A, La Torre D, Chiarella
E, Giovinazzo A, Procopio E, Egiziano MT, Lavano A, Della Torre A.
The
Emerging Role of Senolytics as a Next-Generation Strategy Against
Glioma Recurrence: A Narrative Review.
Cancers
(Basel). 2026 Apr 12;18(8):1220. doi:
10.3390/cancers18081220. PMID:
42073546. ˍ
Wakili MA, Suleiman AB, Majikumna KU,
Shehu HA, Kusetogullari H, Sharif MH.
Vision-Language
Models in Medical Imaging for Cancer Diagnosis: A Bibliometric
Review.
Bioengineering
(Basel). 2026 Apr 16;13(4):466. doi:
10.3390/bioengineering13040466. PMID:
42072260. ˍ
Bihari S, Yang D, Mukherji D, Haggiagi A.
Diffuse
Midline Gliomas: Clinical, Diagnostic, and Therapeutic
Perspectives.
Biomedicines.
2026 Apr 20;14(4):934. doi:
10.3390/biomedicines14040934. PMID:
42072474. ˍ
Wei P, Jiang J, Xiao M, Zhang Y.
Efficacy
and safety of tyrosine kinase inhibitor combination therapy for
glioblastoma: a meta-analysis with trial sequential analysis of
randomized controlled trials.
Front
Oncol. 2026 Apr 20;16:1796708. doi:
10.3389/fonc.2026.1796708. PMID:
42088219. ˍ
Rachamala HR, Lourembam SD, Mukhopadhyay D, Angom RS.
Targeting
Glioblastoma Stem Cells: Therapeutic Strategies and Clinical
Perspectives.
Cancers
(Basel). 2026 Apr 24;18(9):1353. doi:
10.3390/cancers18091353. PMID:
42122149. ˍ
Steindler DA, Karakoula K.
Glioblastoma
Stem Cells as Targets for Emerging Precision Immunotherapies and
Molecular Treatments.
Cells.
2026 Apr 26;15(9):783. doi:
10.3390/cells15090783. PMID:
42121884. ˍ
Nordahl IK, Johnstad C, Solheim O, Torp SH.
Ki-67
and overall survival in patients with glioblastoma: A systematic
prognostic review and meta-analysis.
Neurooncol
Adv. 2026 Apr 27;8(1):vdag111. doi:
10.1093/noajnl/vdag111. PMID:
42211396. ˍ
Pasqualetti F, Ius T, Montemurro N, Bertolotti C, Pivato S,
Padovan M, Caccese M, Bellu L, Morganti R, Acerbi F, Denaro L,
Soffietti R, Ottaviani D, Bocci G, Lombardi G, Krengli M.
Prolonged
sequential temozolomide in glioblastoma: A systematic review with
exploratory quantitative synthesis.
Cancer
Treat Res Commun. 2026 Apr 27;47:101231. doi:
10.1016/j.ctarc.2026.101231. PMID:
42114299. ˍ